Determination and analysis of the gene expression, involved in the differentiation and functioning of beta cells under the conditions of the development of experimental diabetes of the dexamethasone type (type 2 diabetes)
DOI:
https://doi.org/10.14739/2409-2932.2025.1.322232Keywords:
pancreas, diabetes, genes, insulin, insulin resistance, differentiation, beta cells, laboratory diagnosticsAbstract
According to the World Health Organization, the number of patients with diabetes is constantly increasing, making this issue relevant not only for medical science, but also for the healthcare system as a whole. The mechanisms of functioning and differentiation of beta cells of the pancreas have attracted significant scientific attention. Laboratory identification of the genetic mechanisms regulating these processes is crucial for understanding the molecular basis of the development of type 2 diabetes and for finding new approaches to its prevention and treatment.
The aim of the work is to identify and analyze a panel of genes, involved in the differentiation and functioning of beta cells under the conditions of the development of experimental type 2 diabetes.
Materials and methods. Analysis of the gene expression, involved in the differentiation and functioning of beta cells was performed using the real-time reverse transcription polymerase chain reaction method CFX-96 Touch™ (Bio-Rad, USA) using the RT2Profiler™ PCR Array Rat Diabetes kit (QIAGEN, Germany).
Results. According to the results of the PCR study, the activity of the studied genes, involved in the differentiation and functioning of beta cells can be divided as follows: Vapa – a gene with high expression, compared to the control group of animals, Glp1r, Hnf1b, Hnf4a, Inppl 1, Ins 1, Mapk 8, Neurod 1, Stxbp 1, Stxbp 4, Vamp 2, Vamp 3 – genes with low expression, compared to the control group of animals, Nfkb 1, Nsf, Rab4a, Stx 4, Stxbp 2 – genes, in which no changes were detected in the samples in relation to the control group of animals, Pdx 1, Pparg, Ptpn 1, Sod 2 – genes, whose expression was not detected.
Conclusions. The development of type 2 dexamethasone diabetes significantly (where ∆∆Ct <30) increases the expression of the Vapa gene by 2.81 times, compared to the control group of animals. During the development of type 2 dexamethasone diabetes, significantly (where ∆∆Ct <30) genes Glp1r showed a low expression by 5.71 times, Hnf1b by 7.45 times, Hnf4a by 16.06 times, Inppl 1 by 22.81 times, Ins 1 by 9.53 times, Mapk 8 by 2.07 times, Neurod 1 and Stxbp 4 by 3 times, Stxbp 1 by 28.46 times, Vamp 2 and Vamp 3 by 12 times in relation to the control group of animals. The expression of Pdx 1, Pparg, Ptpn 1, Sod 2 genes during the development of type 2 dexamethasone diabetes was not detected.
References
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. doi: https://doi.org/10.1016/j.diabres.2019.107843
Hudish LI, Reusch JE, Sussel L. β Cell dysfunction during progression of metabolic syndrome to type 2 diabetes. J Clin Invest. 2019;129(10):4001-8. doi: https://doi.org/10.1172/JCI129188
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8. doi: https://doi.org/10.1006/meth.2001.1262
Zhang XJ, Li XJ, Xia JL, Yan SX, Ji F, Zhang YC, et al. Expression status of diabetes-associated genes in middle and aged cynomolgus monkeys. Dongwuxue Yanjiu. 2011;32(3):300-6. doi: https://doi.org/10.3724/SP.J.1141.2011.03300
Bailey CJ, Flatt PR, Conlon JM. An update on peptide-based therapies for type 2 diabetes and obesity. Peptides. 2023;161:170939. doi: https://doi.org/10.1016/j.peptides.2023.170939
Huang T, Wang L, Bai M, Zheng J, Yuan D, He Y, et al. Influence of IGF2BP2, HMG20A, and HNF1B genetic polymorphisms on the susceptibility to Type 2 diabetes mellitus in Chinese Han population. Biosci Rep. 2020;40(5):BSR20193955. doi: https://doi.org/10.1042/BSR20193955
Mohlke KL, Boehnke M. The role of HNF4A variants in the risk of type 2 diabetes. Curr Diab Rep. 2005;5(2):149-56. doi: https://doi.org/10.1007/s11892-005-0043-y
Marion E, Kaisaki PJ, Pouillon V, Gueydan C, Levy JC, Bodson A, et al. The gene INPPL1, encoding the lipid phosphatase SHIP2, is a candidate for type 2 diabetes in rat and man. Diabetes. 2002;51(7):2012-7. doi: https://doi.org/10.2337/diabetes.51.7.2012
Kaisaki PJ, Delépine M, Woon PY, Sebag-Montefiore L, Wilder SP, Menzel S, et al. Polymorphisms in type II SH2 domain-containing inositol 5-phosphatase (INPPL1, SHIP2) are associated with physiological abnormalities of the metabolic syndrome. Diabetes. 2004;53(7):1900-4. doi: https://doi.org/10.2337/diabetes.53.7.1900
Ma Y, Wang X, Peng Y, Ding X. Forkhead box O1 promotes INS 1 cell apoptosis by reducing the expression of CD24. Mol Med Rep. 2016;13(4):2991-8. doi: https://doi.org/10.3892/mmr.2016.4896
Yu J, Li X, Cao J, Zhu T, Liang S, Du L, et al. Components of the JNK-MAPK pathway play distinct roles in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2023;149(19):17495-509. doi: https://doi.org/10.1007/s00432-023-05473-9
Lee KI, Su CC, Yang CY, Hung DZ, Lin CT, Lu TH, et al. Etoposide induces pancreatic β-cells cytotoxicity via the JNK/ERK/GSK-3 signaling-mediated mitochondria-dependent apoptosis pathway. Toxicol In Vitro. 2016;36:142-52. doi: https://doi.org/10.1016/j.tiv.2016.07.018
Kim JW, You YH, Jung S, Suh-Kim H, Lee IK, Cho JH, et al. miRNA-30a-5p-mediated silencing of Beta2/NeuroD expression is an important initial event of glucotoxicity-induced beta cell dysfunction in rodent models. Diabetologia. 2013;56(4):847-55. doi: https://doi.org/10.1007/s00125-012-2812-x
Fu X, Shen Y, Wang W, Li X. MiR-30a-5p ameliorates spinal cord injury-induced inflammatory responses and oxidative stress by targeting Neurod 1 through MAPK/ERK signalling. Clin Exp Pharmacol Physiol. 2018;45(1):68-74. doi: https://doi.org/10.1111/1440-1681.12856
Lang H, Ai Z, You Z, Wan Y, Guo W, Xiao J, et al. Characterization of miR-218/322-Stxbp1 pathway in the process of insulin secretion. J Mol Endocrinol. 2015;54(1):65-73. doi: https://doi.org/10.1530/JME-14-0305
Saito T, Okada S, Yamada E, Ohshima K, Shimizu H, Shimomura K, et al. Syntaxin 4 and Synip (syntaxin 4 interacting protein) regulate insulin secretion in the pancreatic beta HC-9 cell. J Biol Chem. 2003;278(38):36718-25. doi: https://doi.org/10.1074/jbc.M305114200
Cheng ZJ, Singh RD, Wang TK, Holicky EL, Wheatley CL, Bernlohr DA, et al. Stimulation of GLUT4 (glucose transporter isoform 4) storage vesicle formation by sphingolipid depletion. Biochem J. 2010;427(1):143-50. doi: https://doi.org/10.1042/BJ20091529
Xu S, Kim JH, Hwang KH, Das R, Quan X, Nguyen TT, et al. Autocrine insulin increases plasma membrane K(ATP) channel via PI3K-VAMP2 pathway in MIN6 cells. Biochem Biophys Res Commun. 2015;468(4):752-7. doi: https://doi.org/10.1016/j.bbrc.2015.11.028
Zhang Y, Fang X, Wei J, Miao R, Wu H, Ma K, et al. PDX-1: A Promising Therapeutic Target to Reverse Diabetes. Biomolecules. 2022;12(12):1785. doi: https://doi.org/10.3390/biom12121785
Wagner R, Hieronimus A, Lamprinou A, Heni M, Hatziagelaki E, Ullrich S, et al. Peroxisome proliferator-activated receptor gamma (PPARG) modulates free fatty acid receptor 1 (FFAR1) dependent insulin secretion in humans. Mol Metab. 2014;3(6):676-80. doi: https://doi.org/10.1016/j.molmet.2014.07.001
Alswat KA, Nasr A, Al Dubayee MS, Talaat IM, Alsulaimani AA, Mohamed IA, et al. The Potential Role of PTPN-22 C1858T Gene Polymorphism in the Pathogenesis of Type 1 Diabetes in Saudi Population. Immunol Invest. 2018;47(5):521-33. doi: https://doi.org/10.1080/08820139.2018.1458109
Bandeira Sde M, Guedes Gda S, da Fonseca LJ, Pires AS, Gelain DP, Moreira JC, et al. Characterization of blood oxidative stress in type 2 diabetes mellitus patients: increase in lipid peroxidation and SOD activity. Oxid Med Cell Longev. 2012;2012:819310. doi: https://doi.org/10.1155/2012/819310
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. 
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
